טוען...
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
BACKGROUND: As neoadjuvant chemotherapy (NAC) is increasingly used in triple-negative breast cancer (TNBC), we investigated the value of circulating tumor DNA (ctDNA) for patient monitoring prior, during, and after NAC, and circulating tumor cells (CTCs) for disease characterization at clinical prog...
שמור ב:
| הוצא לאור ב: | ESMO Open |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8010400/ https://ncbi.nlm.nih.gov/pubmed/33743331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100086 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|